Therapy Areas: Oncology
Shorla Pharma Names Holsman as Chief Commercial Officer
4 March 2021 - - Ireland-based specialty pharmaceutical company Shorla Pharma Ltd has named Nicholas Holsman as chief commercial officer, the company said.

Shorla specializes in developing innovative oncology drugs, with a focus on orphan and pediatric cancers.

With a strong team of scientists, clinicians and an extensive industry network, the company has an advanced pipeline of drug products to treat a number of unmet patient needs.

Holsman has almost twenty years' experience in leading commercial functions, with a focus on high growth start-up biotech companies.

Most recently, he was Head of Commercial Operations at Oncopeptides, INC, where he was responsible for building the infrastructure to support the launch of Pepaxto, a peptide-conjugated alkylator for the treatment of relapsed and refractory multiple myeloma patients.

Before Oncopeptides, Holsman spent nearly four years leading the commercial efforts at KemPharm Inc as senior director of commercial strategy and market access and held roles of growing responsibility at Gilead and Symphony Health.

Established in 2018 by Sharon Cunningham and Orlaith Ryan, Shorla Pharma Ltd is a privately held, Ireland based specialty pharmaceutical company with an advanced pipeline of innovative oncology drugs for women's, orphan and pediatric cancers.

The company concentrates on indications where existing treatments are limited, in shortage or inadequate for the target population.


Related Headlines